GRPR targeting theranostic - Starget Pharma
Latest Information Update: 11 Apr 2025
At a glance
- Originator Starget Pharma
- Class Antineoplastics; Peptides; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer; Gastrointestinal stromal tumours; Lung cancer; Prostate cancer
Most Recent Events
- 27 Mar 2025 Preclinical trials in Breast cancer (Diagnosis) in Israel (unspecified route) prior to March 2025 (Starget Pharma pipeline, March 2025)
- 27 Mar 2025 Preclinical trials in Breast cancer in Israel (unspecified route) prior to March 2025 (Starget Pharma pipeline, March 2025)
- 27 Mar 2025 Preclinical trials in Gastrointestinal stromal tumours (Diagnosis) in Israel (unspecified route) prior to March 2025 (Starget Pharma pipeline, March 2025)